HVAD: The ENDURANCE Supplemental Trial

2018221 citationsJournal Articlehybrid Open Access

Authors

Carmelo A. Milano · Duke University

Joseph G. Rogers · Duke University

Antone Tatooles · Advocate Christ Medical Center

Geetha Bhat · Advocate Christ Medical Center

Mark S. Slaughter · University of Louisville

Emma J. Birks · University of Louisville

Nahush A. Mokadam ·

Abstract

The ENDURANCE Supplemental Trial failed to demonstrate noninferiority of HVAD versus control regarding the pre-specified primary endpoint. However, the trial confirmed that BP management is associated with reduced stroke rates in HVAD subjects. HVAD subjects, relative to control subjects, more commonly achieved the composite endpoint (freedom from death, disabling stroke, and device replacement or urgent transplantation). (A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System [ENDURANCE SUPPLEMENTAL TRIAL] [DT2]; NCT01966458).

Topics & Keywords

Mechanical Circulatory Support Devices Cardiac Arrest and Resuscitation Cardiac Structural Anomalies and Repair

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JACC Heart Failure

Volume 6, Issue 9, pp. 792-802

DOI: 10.1016/j.jchf.2018.05.012

Field-Weighted Citation Impact: 15.53